Freenome (NASDAQ:FRNM) Short Interest Up 217.8% in August

Freenome (NASDAQ:FRNM) saw a significant increase in short interest in August. As of August 14th, there was short interest totaling 1,416,509 shares, an increase of 217.8% from the July 30th total of 445,737 shares. Approximately 22.3% of the company’s shares are short sold. Based on an average trading volume of 808,742 shares, the short-interest ratio is currently 1.8 days.

Freenome Trading Up 6.1%

Shares of NASDAQ FRNM traded up $0.85 during mid-day trading on Friday, reaching $14.79. The company had a trading volume of 1,713,654 shares, compared to its average volume of 868,911. The stock has a market cap of $120.69 million, a PE ratio of -246.46 and a beta of 0.35. Freenome has a 52 week low of $9.97 and a 52 week high of $15.09.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on FRNM shares. TD Cowen initiated coverage on Freenome in a research report on Tuesday, August 18th. They set a “buy” rating and a $17.00 price objective on the stock. Weiss Ratings assumed coverage on Freenome in a report on Monday. They issued a “sell (d+)” rating for the company. Jefferies Financial Group initiated coverage on Freenome in a research report on Monday, August 17th. They set a “buy” rating and a $17.00 target price on the stock. Guggenheim began coverage on Freenome in a report on Thursday, August 20th. They set a “buy” rating and a $21.00 price target on the stock. Finally, BTIG Research initiated coverage on Freenome in a research report on Monday, August 17th. They issued a “buy” rating and a $17.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Freenome currently has an average rating of “Moderate Buy” and an average price target of $18.00.

About Freenome

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.